CN119156202A - 包含阿替卡普兰的组合物 - Google Patents

包含阿替卡普兰的组合物 Download PDF

Info

Publication number
CN119156202A
CN119156202A CN202380038806.7A CN202380038806A CN119156202A CN 119156202 A CN119156202 A CN 119156202A CN 202380038806 A CN202380038806 A CN 202380038806A CN 119156202 A CN119156202 A CN 119156202A
Authority
CN
China
Prior art keywords
treatment
pharmaceutical composition
hours
patient
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380038806.7A
Other languages
English (en)
Chinese (zh)
Inventor
N·M·F·戈伊瓦茨
M·施密特
V·波波瓦
A·J·萨维茨
R·梅尔科特
W·C·德雷维茨
M·D·S·戈帕尔
D·彭伯顿
C·拉吉谢蒂
I·克日奇
M·N·萨姆塔尼
T·休布雷希特
G·范德沃特
M·拉维林根
L·M·马科斯
T·马尔科齐
K·约基切维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CN119156202A publication Critical patent/CN119156202A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380038806.7A 2022-03-07 2023-03-06 包含阿替卡普兰的组合物 Pending CN119156202A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317471P 2022-03-07 2022-03-07
US63/317471 2022-03-07
PCT/IB2023/052097 WO2023170554A1 (en) 2022-03-07 2023-03-06 Compositions comprising aticaprant

Publications (1)

Publication Number Publication Date
CN119156202A true CN119156202A (zh) 2024-12-17

Family

ID=85980700

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380038806.7A Pending CN119156202A (zh) 2022-03-07 2023-03-06 包含阿替卡普兰的组合物

Country Status (15)

Country Link
US (3) US20230277500A1 (https=)
EP (1) EP4489730B1 (https=)
JP (1) JP2025508069A (https=)
KR (1) KR20240152410A (https=)
CN (1) CN119156202A (https=)
AU (1) AU2023231767A1 (https=)
CA (1) CA3254546A1 (https=)
CL (1) CL2024002648A1 (https=)
CO (1) CO2024012454A2 (https=)
IL (1) IL315415A (https=)
JO (1) JOP20240196A1 (https=)
MX (1) MX2024010977A (https=)
TW (1) TW202400135A (https=)
UY (1) UY40173A (https=)
WO (1) WO2023170554A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186873A1 (en) * 2008-01-22 2009-07-23 Nuria Diaz Buezo Kappa selective opioid receptor antagonist
CN102724970A (zh) * 2009-11-09 2012-10-10 惠氏有限责任公司 来那替尼马来酸盐的片剂制剂
CN108135854A (zh) * 2015-06-30 2018-06-08 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
TR200103237T2 (tr) 1999-05-12 2002-04-22 F. Hoffmann-La Roche Ag İmidazodiazepin türevi
US20020052365A1 (en) 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE60319812T2 (de) 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
KR101025633B1 (ko) 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
ATE406360T1 (de) 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
EP1613597B1 (en) 2003-03-07 2007-11-07 Eli Lilly and Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
CA2549009A1 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
ES2390459T3 (es) 2003-12-22 2012-11-13 Eli Lilly And Company Antagonistas de receptores de opioides
DE602005022572D1 (de) 2004-03-12 2010-09-09 Lilly Co Eli Antagonisten des opioidrezeptors
ATE399164T1 (de) 2004-03-12 2008-07-15 Lilly Co Eli Antagonisten des opioidrezeptors
EP1729759A4 (en) 2004-03-12 2008-04-02 Mclean Hospital Corp SALVINORINE DERIVATIVES AND ITS USES
DE602005012380D1 (de) 2004-03-15 2009-03-05 Lilly Co Eli 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit
EP1735268B1 (en) 2004-03-15 2012-02-15 Eli Lilly And Company Opioid receptor antagonists
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
JP5128578B2 (ja) 2006-04-04 2013-01-23 エモディス ゲーエムベーハー 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用
EP2049481A2 (en) 2006-08-09 2009-04-22 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
EP2054383A2 (en) 2006-08-09 2009-05-06 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
KR20090051778A (ko) 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
WO2012016569A1 (en) 2010-08-05 2012-02-09 Conrig Pharma Aps Deuterated tandospirone derivatives as 5-ht1a receptor agonists
ES2631607T3 (es) 2011-12-09 2017-09-01 Research Triangle Institute, International 4-Arilpiperazinas 1-sustituidas como antagonistas del receptor opioide kappa
ES2694352T3 (es) 2013-12-20 2018-12-20 H. Lundbeck A/S Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas
WO2016156396A1 (en) 2015-03-30 2016-10-06 University Of Innsbruck Diphenethylamine derivatives which are inter alia useful as analgesics and methods for their production
US10709685B2 (en) 2015-05-28 2020-07-14 Georgetown University Use of methadone metabolites for treatment of anxiety and depression
EP3468540A4 (en) 2016-06-13 2020-03-18 Board Of Regents Of the University Of Texas System PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
US20190240293A1 (en) 2016-07-26 2019-08-08 Flagship Pioneering Innovations V, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response
US11292783B2 (en) 2016-09-16 2022-04-05 Research Triangle Institute Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
AU2018234931B2 (en) 2017-03-17 2022-05-26 Blackthorn Therapeutics, Inc. Kappa opioid receptor antagonists and products and methods related thereto
PH12018000077B1 (en) * 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US20190255036A1 (en) 2018-02-16 2019-08-22 Alexander Kariman Compound and method for reducing neuropathic pain and depression
JP7416751B2 (ja) 2018-03-23 2024-01-17 ユニバーシティ オブ カンザス 環状テトラペプチド類似体
US11491144B2 (en) 2018-03-30 2022-11-08 The Florida State University Research Foundation, Incorporated Methods of treating fragile X mental retardation syndrome
EP3870030A4 (en) 2018-10-23 2022-08-03 Blackthorn Therapeutics, Inc. SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS AND STRATIFICATION OF PATIENTS
US20200171025A1 (en) * 2018-11-29 2020-06-04 Srinivasa Rao Parella Pharmaceutical composition comprising brexpiprazole and process for preparation thereof
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
PH12023552963A1 (en) * 2021-05-04 2024-03-11 Janssen Pharmaceuticals Inc Compositions and methods for the treatment of depression
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
AU2023231493A1 (en) 2022-03-07 2024-10-24 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090186873A1 (en) * 2008-01-22 2009-07-23 Nuria Diaz Buezo Kappa selective opioid receptor antagonist
CN102724970A (zh) * 2009-11-09 2012-10-10 惠氏有限责任公司 来那替尼马来酸盐的片剂制剂
CN108135854A (zh) * 2015-06-30 2018-06-08 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDREW D. KRYSTAL: "A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia", NATURE MEDICINE, vol. 26, no. 5, 20 March 2020 (2020-03-20), pages 10, XP037113592, DOI: 10.1038/s41591-020-0806-7 *

Also Published As

Publication number Publication date
CA3254546A1 (en) 2023-09-14
IL315415A (en) 2024-11-01
EP4489730B1 (en) 2026-01-21
JP2025508069A (ja) 2025-03-21
MX2024010977A (es) 2024-12-06
WO2023170554A1 (en) 2023-09-14
US20230277500A1 (en) 2023-09-07
EP4489730C0 (en) 2026-01-21
AU2023231767A1 (en) 2024-10-24
EP4489730A1 (en) 2025-01-15
US12201610B2 (en) 2025-01-21
CO2024012454A2 (es) 2024-09-30
US20240269110A1 (en) 2024-08-15
KR20240152410A (ko) 2024-10-21
TW202400135A (zh) 2024-01-01
CL2024002648A1 (es) 2025-01-24
US20250228819A1 (en) 2025-07-17
UY40173A (es) 2023-09-29
JOP20240196A1 (ar) 2024-09-05

Similar Documents

Publication Publication Date Title
CN119156202A (zh) 包含阿替卡普兰的组合物
EP3209298B1 (en) Compositions for treating insomnia
CN107849021A (zh) 治疗炎症或神经性疼痛的方法
US11826321B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN115776894A (zh) T型钙通道调节剂的使用方法
TW202313003A (zh) 用於治療憂鬱之組成物及方法
CN119156210A (zh) 纯形式的结晶阿替卡普兰
US20240197756A1 (en) Methods of treatment with neuroactive steroids
CN119156211A (zh) 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
JP2026506102A (ja) 疼痛緩和に有用なレジメンおよび組成物
EP4642445A2 (en) Methods of administering r-ketamine
WO2024129782A1 (en) Regimens and compositions useful for alleviating pain
US20250295648A1 (en) Method for treating l-dopa-induced dyskinesia, parkinson's disease, or parkinson's disease motor disability using befiradol
CN121969364A (zh) 用于在治疗重性抑郁障碍中使用的包含阿替卡普兰的组合物
US20240358693A1 (en) Methods of treating pain
WO2024196957A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
KR20250165616A (ko) 고함량 단일 투여 단위 제형 및 이의 사용 방법
WO2025245066A1 (en) Compositions and methods for affecting weight loss, weight management, sexual disorders, well-being, self-esteem, and/or self-confidence
WO2011051423A1 (en) Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy
EP4633628A1 (en) Regimens and compositions useful for alleviating pain
CN117615757A (zh) 用于治疗抑郁症的组合物和方法
WO2021146425A1 (en) Methods of treating acute muscle spasms
NZ614725B2 (en) Methods and compositions for treating depression using cyclobenzaprine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination